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Abstract
Background: Slow waves in the delta (0.5–4 Hz) frequency range are indications of normal activity
in sleep. In neurological disorders, focal electric and magnetic slow wave activity is generated in the
vicinity of structural brain lesions. Initial studies, including our own, suggest that the distribution of
the focal concentration of generators of slow waves (dipole density in the delta frequency band)
also distinguishes patients with psychiatric disorders such as schizophrenia, affective disorders, and
posttraumatic stress disorder.
Methods:  The present study examined the distribution of focal slow wave activity (ASWA:
abnormal slow wave activity) in116 healthy subjects, 76 inpatients with schizophrenic or
schizoaffective diagnoses and 42 inpatients with affective (ICD-10: F3) or neurotic/reactive (F4)
diagnoses using a newly refined measure of dipole density. Based on 5-min resting
magnetoencephalogram (MEG), sources of activity in the 1–4 Hz frequency band were determined
by equivalent dipole fitting in anatomically defined cortical regions.
Results: Compared to healthy subjects the schizophrenia sample was characterized by significantly
more intense slow wave activity, with maxima in frontal and central areas. In contrast, affective
disorder patients exhibited less slow wave generators mainly in frontal and central regions when
compared to healthy subjects and schizophrenia patients. In both samples, frontal ASWA were
related to affective symptoms.
Conclusion: In schizophrenic patients, the regions of ASWA correspond to those identified for
gray matter loss. This suggests that ASWA might be evaluated as a measure of altered neuronal
network architecture and communication, which may mediate psychopathological signs.
Background
Slow wave electrocortical activity composed of large
amplitude and low frequency activity in the delta (0.5–4
Hz) or theta (4–7 Hz) frequency bands can be seen in nor-
mal sleep stages; this has been mainly reported for electro-
encephalogram (EEG) but also for
magnetoencephalogram (MEG) measurements [1].
Although mainly associated with brain quiescence and
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the closing of thalamic gates for external input, such activ-
ity has also been related to unexpected high levels of
spontaneous neuronal activity, which may serve impor-
tant cognitive processes such as memory consolidation
[2,3]. This raises the question of how to understand slow
wave activity in waking states. Traditionally, delta activity
in the waking state has mainly been of interest to those
studying neurological disorders. Slow wave rhythms are
found in a variety of developmental and degenerative dis-
orders, in toxic and metabolic encephalopathy and in
other neurological conditions. Focally concentrated slow
waves appear in the vicinity of a structural lesion such as
cerebral infarct, contusion, local infection, tumor, epilep-
tic foci and subdural hematoma [4-16]. Abnormal slow
wave activity (ASWA) has been attributed to a 'dysfunc-
tional state' of the generating neuronal tissue [17], due to
changes in metabolism and blood flow consequent upon
insult [11,12,18] or due to 'deafferentation' of neural net-
works that have been cut off from major input sources.
Generators of slow wave activity in cortical and subcorti-
cal structures were initially determined from intracranial
electrodes. More recently, magnetic source imaging (MSI)
has been used to identify cortical generators through
dipole density measurement from the MEG
[7,8,12,13,19,20]. Using this procedure, we confirmed
left-hemispheric slow wave clusters in aphasic patients
suffering from ischemic or hemorrhagic lesions affecting
the left hemisphere [21].
Abnormalities in the EEG or MEG power spectra have also
been reported in psychiatric disorders. For instance, aug-
mented activity in the lower EEG- or MEG-frequency
bands which can be either diffuse or focused over distinct
brain regions has been reported for a variety of psychiatric
disorders such as schizophrenia [22-27], dementia
[20,28,29], and posttraumatic stress disorder (PTSD;
[[30], and: Kolassa IT, Wienbruch C, Neuner F, Schauer M,
Ruf M, Odenwald M, Elbert T: Imaging the trauma: altered
cortical dynamics after repeated traumatic stress, submit-
ted]. It has also been observed in symptoms related to
deafferentation such as tinnitus [31], which is linked to
hearing loss. Overall, such spectral abnormalities seem to
be related to brain reorganization in response to lesion
and deafferentation rather than to a particular disease. Lli-
nas and coworkers [32] concluded from the magnification
of MEG-slow waves in various disorders (e.g., tinnitus,
obsessive compulsive disorder, depression) that the sur-
face phenomenon reflected subcortical dysfunction or
thalamo-cortical dysrhythmia. Using magnetic source
imaging and dipole density measurement, researchers
have also found specific distributions of abnormality in
network dynamics of schizophrenic patients [19,33-36].
The present study used spontaneous MEG as bases for
source analyses, which has some advantages for this pur-
pose in comparison to EEG. One advantage is that MEG
by its nature separates focally generated slow waves from
those with widespread sources [37]. Another advantage is
that MEG is better able than EEG to identify focal sources
located in sulci which comprise two-thirds of the cortex.
Thus, the same brain processes are pictured differently by
MEG and EEG, and combined measurements of both
MEG and EEG quantitatively illustrate this point [38].
The purpose of the present study is to extend our previous
results that were obtained from smaller samples [19,35]
by employing a more specific method of slow wave map-
ping with a sample of 116 healthy subjects, a sample of 42
individuals with affective (F3) or neurotic/reactive (F4)
disorders and a sample of 76 patients with diagnoses from
the schizophrenia spectrum. Given the ability of focal
abnormal slow wave mapping to disclose dysfunctional
or reorganized brain areas in neurology [21], we asked
whether the distribution of ASWA or its focal concentra-
tion might index altered brain areas even in the absence of
structurally obvious lesions, thereby offering a signature
of potentially dysfunctional neuronal network architec-
ture and communication in psychiatric disorders as addi-
tional diagnostic information. Given a potentially clinical
relevance, we designed recording and analyses brief and
economic, and we did not pre-select specific subgroups
but rather evaluated potential impact of medication and
substance abuse in post-hoc analyses.
Whereas a number of studies have verified the significance
of abnormal slow waves in neurological disorders, its sig-
nificance in psychiatric patients still has to be substanti-
ated. Therefore, the present study sought to determine if
abnormal slow wave activity would also be present in
individuals with a variety of psychopathologies. From pre-
vious studies including our own, we expected significant
differences of ASWA (intensity and distribution) in psy-
chiatric patients compared to healthy subjects. Further, we
expected more abnormal slow wave activity in schizo-
phrenia patients than in healthy subjects. Additionally,
exploratory analysis with relevant clinical variables will
help to inform future research regarding the functional
significance of ASWA.
Methods
Design
Five-minute recordings of spontaneous MEG were
obtained from 116 healthy subjects, 76 individuals with
schizophrenia and 42 individuals with affective disorders.
No task or intervention was induced.BMC Psychiatry 2007, 7:44 http://www.biomedcentral.com/1471-244X/7/44
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Participants
The schizophrenia sample consisted of 76 inpatients (62
males, 14 females; 29.12 ± 8.0 years of age (mean ± SD)
diagnosed and treated for schizophrenia or schizoaffec-
tive disorder from a university inpatient research unit at
the local Center for Psychiatry. Male patients were non-
significantly younger (28.53 ± 7.9 years) than females
(31.71 ± 7.7 years; t(74) = 1.36, p = .18). Diagnosed by
experienced senior psychiatrists using ICD-10 criteria, the
majority of patients (N = 61, 49 male) received F20 diag-
noses, the remaining subjects receiving diagnoses of
schizoaffective disorder (F25, N = 9, 7 male) or F23 cate-
gory (N = 6, 6 male). Duration of illness varied between 0
(first admission) and 22 years around a mean of 5.78 ±
5.8 years, and did not differ between male (5.40 ± 5.9)
and female patients (7.5 ± 5.3; t(63) = 1.13, p = .26).
Mean age at first admission varied around a mean of
23.22 ± 5.4 years, with (non-significantly) earlier age of
onset in male (22.77 ± 5.3 years) than in female patients
(25.17 ± 6.0 years, t(63) = 1.39, p = .17). Duration of ill-
ness was related to age (r = .71, p = .0001), but not to the
age of first admission (r = -.07). As co-diagnoses, 29
patients (all male) met the criteria of cannabis abuse
(F12.1) or dependency (12.2), and 5 patients received the
co-diagnoses of alcohol abuse (F19.1). Among the 40
patients without drug abuse history, 29 were male and 11
female. The symptom profile was characterized by PANSS
(Positive and Negative Symptom Scale) [39] and BPRS
(Brief Psychiatric Rating Scale) [40] (PANSS-P: 14.13 ± 5.0
(range 7–26); PANSS-N: 21.26 ± 6.3 (7–33); PANSS-G:
35.26 ± 7.7 (21–62); BPRS (available from 44 subjects):
42.67 ± 10.7 (25–79). At the time of the investigation
only 7 patients were not under neuroleptic medication.
The other patients received traditional (N = 14), atypical
neuroleptics (N = 41) or a combination of both (N = 14).
Eight patients were left-handed as verified by a modified
version of the Edinburgh Handedness Questionnaire
[41]. Since handedness may affect the topography of brain
activity, in particular hemispheric asymmetry, analyses
were repeated without the left-handers. Given that the
results did not differ, we concluded that handedness did
not have a crucial impact on the present dependent varia-
bles and report results for the entire sample of 76 patients.
The group of inpatients diagnosed and treated for affec-
tive/neurotic disorders (diagnostic categories below) com-
prised 42 (13 males, mean age 45.1 ± 8.5 years) subjects.
Data from 20 patients from an earlier study [19] were re-
analyzed with the new method, and 22 patients were
additionally recruited for the present study. Eighteen
patients were diagnosed as suffering from severe major
depressive episode (ICD-10: F32), sixteen from recurrent
depressive episodes (F33), and eight from neurotic, reac-
tive and somatoform disorders (F4). In terms of medica-
tion, thirty-six patients received antidepressive
medication including tricyclic antidepressants (TCA, N =
13), selective serotonin reuptake inhibitors (SSRI, N = 7),
a combination of both (N = 5) or a combination with
neuroleptics or mood stabilizers (N = 11). The severity of
depressive symptoms at the time of the investigation was
assessed by the Beck Depression Inventory (BDI, mean of
25.1 ± 9.91, range 1–49). In addition, the BPRS was avail-
able for 22 patients (mean ± SD 49.73 ± 10.9, range 32–
77). All subjects in the depressive sample were right-
handed as verified by the Edinburgh Handedness Ques-
tionnaire.
The sample of healthy subjects comprised 116 individuals
(59 males, mean age 28.95 ± 10.16 years), who had never
been treated for a neurological or psychiatric disorder and
were not under medication (other than vitamins or con-
traceptives). All subjects were right-handed as verified by
the Edinburgh Handedness Questionnaire. In all of our
studies, healthy controls were matched in terms of age
and gender to individuals with the psychiatric group
investigated in the specific study. This resulted in a com-
bined group of healthy subjects varying in age in relation
to the psychopathology groups. The overall healthy sub-
jects group was comparable to the schizophrenia sample
with respect to age (t<1), whereas patients with affective
diagnoses were significantly older than healthy subjects
(t(156) = 9.21, p = .0001) and schizophrenic patients
(t(116) = 10.20, p = .0001).
Data acquisition and analysis
Using a 148-channel whole-head neuromagnetometer
(MAGNES™ 2500 WH, 4D Neuroimaging, San Diego,
USA) the MEG was measured during a 5-minute resting
period using 678.17 Hz sampling rate and real bandpass
filter of 0.1–200 Hz. Recordings were obtained in a lying
position. Subjects were asked to relax but stay awake and
not engage in any specific mental activity. They were fur-
ther asked to fixate a mark on the ceiling of the magneti-
cally shielded room throughout the recording in order to
avoid eye- and head-movement. A video camera installed
inside the chamber allowed monitoring the subject's
behavior and compliance at any time throughout the
measurement. The subject's index points and head shape
were digitized with a Polhemus 3Space® Fasttrack prior to
each measurement. In specific the nasion point, an ana-
tomical landmark, and the left and right ear canal points
served as index points and were used to define a right
handed coordinate system, called headframe coordinate
system. The x-axis points to the front, the y-axis to the left
and the z-axis to the top of the head. The headshape infor-
mation is used in the standard analysis software for local-
ization of activity sources (4D Neuroimaging – WHS
1.2.6) by fitting a local sphere to the head shape under-
neath the selected channel groups. The subject's headBMC Psychiatry 2007, 7:44 http://www.biomedcentral.com/1471-244X/7/44
Page 4 of 10
(page number not for citation purposes)
position relative to the pickup coils of the sensor was esti-
mated before and after each measurement.
ASWA generators were identified in a semi-automated
procedure. Following noise reduction, data were screened
for artifacts (e.g., eye blinks, muscle activity) by visual
inspection. Data were then reduced by a factor of 16 (anti-
alias filters are applied automatically in the same process-
ing step; new sampling rate of 42.4 Hz) and digitally fil-
tered for the delta (1.5–4.0 Hz) frequency band using a
digital band pass filter (Butterworth filter). Single equiva-
lent current dipoles (ECD) were fitted for each time point
in the selected artifact free segments; the selection of spe-
cific dipole solutions had to meet the criteria Goodness of
Fit (GoF > 0.90, to ensure the statistical significance of the
source model) and Dipole moment (Q 10 – 100 nAm,
which may require that at least 0.1 – 1 cm2 of cortex is acti-
vated). Dipoles with an inferior-superior coordinate (z)
below 0.0 cm and dipoles within a sphere with a radius of
3 cm around the origin were excluded. Dipole density was
estimated within a volume defined as a cube divided into
voxel with a size of 2 × 2 × 2 cm3. The cube is determined
from an ACPC (anterior commissural (AC) – posterior
commissural (PC)) based coordinate system, which, in
turn, results from the individual headframe coordinate
system, defined by the nasion, the left and the right ear
channel). Each source volume (cube) comprises 1331
voxel. Each equivalent dipole is assigned to one voxel of
the source volume, and the number of dipoles within a
voxel is counted. As artifact-free time periods vary
between subjects the dipole density was normalized by
the subject's individual number of artifact free time
points.
The normalized dipole density was calculated for each
subject within each voxel of the source volume; then the
logarithm of the normalized dipole density was calculated
in order to obtain a normal distribution across subjects.
For group comparison and visualization the distribution
was z-transformed using mean and standard deviation
from the healthy subjects group. This score of ASWA, for
the deviation from normal was labeled Z. For the analysis
of the ASWA distribution, dipole density was determined
within anatomically defined brain areas, which were spec-
ified for temporal, frontal, central and parietal areas of the
brain within each hemisphere following the classification
of the anatomical atlas provided with MRICRO's AAL
[42]. Within these 8 regions dipole density was estimated
as the average of the voxel-based dipole density (that is,
Z). The entire procedure is described in detail elsewhere
[43].
For the dependent variable Z, group differences and topo-
graphical characteristics were evaluated by repeated-meas-
ures analyses of variance (ANOVA) including the between
subjects variables Group (comparing the two patient
groups and the healthy subjects group), Gender (compar-
ing male and female subjects within each sample), Hemi-
sphere (comparing the 4 left- and the 4 right-hemispheric
regions) and Region (comparing the anatomically defined
frontal, temporal, central, and parietal cortical areas).
Normal distribution of the data of all three samples was
evaluated in each of the eight regions using the Shapiro-
Wilks test. Separate ANOVA and correlation analyses
served to explore the effects of clinical variables (like med-
ication, drug abuse, and duration of illness) on the ASWA
distribution within the patient groups.
Results
The interaction Group × Region (F(6,687) = 12.30, p <
.0001), and main effects Group (F(2,229) = 18.13, p <
.0001) and Region (F(3,687) = 4.17, p < .001) suggest sig-
nificant and region-specific differences between groups.
These three effects remained statistically significant, if age
was included as a covariate or if the age-range was
restricted to 30–50 years within each group.
Figure 1 illustrates areas of slow wave activity in patients
with schizophrenia and affective/neurotic disorders,
which differ from the topography in the healthy subjects
group. Enhanced ASWA was found in schizophrenic
patients (for the subset of data including only healthy
subjects and schizophrenia patients: Group, F(1,190) =
19.19, p = .0001). The abnormality was accentuated in
central and frontal areas (Group × Region, F(3,570) =
4.84, p = .0025). In contrast, the inpatients with affective
diagnoses exhibited less ASWA than healthy subjects in
frontal and central regions, whereas ASWA did not differ
significantly from healthy individuals in posterior and
temporal regions. Figure 2 illustrates that the fronto-cen-
tral group differences emerge for the entire age range
tested.
Post-hoc planned comparisons confirmed significant dif-
ferences between healthy subjects and schizophrenic
patients, healthy subjects and affective/neurotic disorder
patients, and schizophrenic and affective/neurotic disor-
der patients for frontal (p < .0001) and central (p < .0001)
regions, but not for parieto-occipital (p > .1) and temporal
regions (where only schizophrenic patients tended to
show larger ASWA than healthy subjects, t(190) = 1.86, p
= .065).
Within the schizophrenia sample ASWA distribution did
not differ between gender. Patients treated with tradi-
tional neuroleptics (N = 14) displayed the least ASWA
whereas unmedicated patients (N = 7) showed the most
pronounced ASWA. In patients under atypical medication
or a combination of traditional and atypical was more
similar to unmedicated than to traditionally medicatedBMC Psychiatry 2007, 7:44 http://www.biomedcentral.com/1471-244X/7/44
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patients (medication group, F(3,72) = 2.73, p = .05); the
distribution of ASWA was not affected by medication
(Medication group × Region, F<1). Whereas general eval-
uation of the symptom state by PANSS and BPRS sum
scores was not significantly related to ASWA or its distri-
bution, the average fronto-central ASWA was correlated
with the BPRS items reflecting affective symptoms: Higher
BPRS-depression scores were related to less fronto-central
ASWA (r = -.30, p = .06), but higher BPRS-affective flatten-
ing, if at all, tended to be related to more frontal ASWA (r
= .28, p = .09). In particular those subjects with more pro-
nounced affective flattening and less pronounced depres-
sion (defined as the difference between the two scores)
displayed more fronto-central ASWA (r = .46, p < .01).
Multiple regression analysis confirmed that average
fronto-central ASWA could be significantly predicted (r2 =
.56, F = 5.15, p = .005) by BPRS affective flattening,
depression (negative load) and PANSS-P (but not by age,
duration or age of hospitalization or other symptom
scales).
There was a complex relationship between ASWA distribu-
tion, demographic and clinical variables: Age varied with
ASWA and affected BPRS-depression in male patients (r =
+41, p = .02), but did not contribute significantly to the
relationship between fronto-central ASWA and symptoms
in regression analysis. Symptom severity (assessed by the
BPRS) varied with medication, being higher in unmedi-
cated patients than in patients treated with traditional
(t(10) = 2.32, p = .043) and atypical neuroleptics (t(30) =
3.82, p = .0006), while BPRS-depression score was lower
under atypical medication than in non-mediated patients
(t(26) = 2.66, p = .013). But whereas groups markedly dif-
fered in symptoms, there was no significant difference in
the distribution of ASWA between subjects receiving atyp-
ical neuroleptics and unmedicated patients. Cannabis-
Projection of Z-scores (see method section for description of this measure) for patients with schizophrenia (upper two rows)  and with affective or neurotic/reactive diagnoses (lower two rows) onto outer surface (left column) and inner view (second  left column) of the brain hemispheres Figure 1
Projection of Z-scores (see method section for description of this measure) for patients with schizophrenia (upper two rows) 
and with affective or neurotic/reactive diagnoses (lower two rows) onto outer surface (left column) and inner view (second 
left column) of the brain hemispheres. The letters 'L' and 'R' behind the diagnostic groups indicate the left hemispheric and the 
right hemispheric views. Z-scores depict ASWA relative to the group of 116 healthy subjects with colors indicating the range 
of deviation from the healthy subject group; they vary between large deviation (red color = Z-scores > 0.4) to reverse devia-
tion (lower ASWA relative to the healthy subject group; blue color = Z-scores > -0.4); small to negligible deviation from nor-
mal is depicted by green color. The segmented brain was calculated using the software package Caret (Van Essen DC, Drury 
HA, Dickson J, Harwell J, Hanlon D, Anderson CH (2001) An integrated software suite for surface-based analyses of cerebral 
cortex. J Am Med Inform Assoc, 8: 443–59), overlays of ASWA and the voxel based t-test results are based on AFNI/SUMA 
(Cox RW (1996) AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed 
Res, 29, 162–73).BMC Psychiatry 2007, 7:44 http://www.biomedcentral.com/1471-244X/7/44
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abuse was not related to symptom scores or medication,
although cannabis-abusers were younger than non-users
(t(72) = 4.09, p = .0001).
Within the sample of patients with affective or neurotic
diagnoses, multiple regressional analysis disclosed that
BPRS-depression could be predicted from the mean fron-
tal (average of left- and right-frontal region) and the mean
parieto-occipital ASWA (F = 3.59, p = .047); this relation-
ship was mainly explained by frontal ASWA, that is, those
patients who were rated as more depressed by psychia-
trists, exhibited less frontal slow wave activity (R = -.48, t
= -2.56, p = .02), but a tendency towards more parieto-
occipital ASWA (R = .27 p = .07).
Discussion
The present study builds upon previous studies showing
that the distribution of generators of slow wave activity in
the delta (0.5–4 Hz) frequency range distinguishes indi-
viduals suffering from psychiatric disorders from healthy
individuals. Overall, we found that both individuals with
schizophrenia and those with affective or neurotic/reac-
tive diagnoses differ from healthy controls. In particular,
schizophrenic patients show more abnormal slow wave
activity (ASWA) than both a patient group with affective/
neurotic diagnoses and a group of healthy subjects. Con-
versely, the affective/neurotic disorder group showed less
slow wave activity than the other two groups in frontal
and central areas. Less frontal activity was also seen in
schizophrenia patients with higher BPRS-scores of depres-
sion. Thus, our results demonstrate the ability of ASWA to
distinguish between psychopathological groups and con-
trols. This raises two questions: (a) what factors may be
driving abnormal slow wave activity and (b) can the
measurement add clinically useful information?
Schizophrenic patients in our present study are character-
ized by extended and excessive slow wave activity, which
adds to earlier findings from our [19,35,36] and other
groups [33,34,44,45]. An important finding of the present
study is the correspondence of abnormal slow wave activ-
ity in those areas that previous studies have associated
with gray matter loss in schizophrenia [e.g. [46,47]]. In
particular we found the prominence of abnormal slow
wave activity to be in the central area of the cortex com-
prising anatomical areas from precentral and supplemen-
tary motor areas to superior and inferior parietal lobes
and the middle part of the cingulate gyrus, and in frontal
regions comprising orbitofrontal, medial and superior
frontal areas with the latter corresponding to dorsolateral
prefrontal cortex and the anterior part of the cingulum.
Centro-parietal) ASWA was even more pronounced in
younger patients with schizophrenia whereas the varia-
tion of age with anterior (centro-frontal) ASWA only
approached significance. Although the present data do
not allow specific conclusions in this respect, they may be
hypothetically related to reports of a more posterior start
of gray matter loss in adolescents with early onset schizo-
phrenia and with later progression to frontal (including
orbitofrontal and dorsolateral prefrontal cortex [48-50]
and temporal regions [51]). A widespread distribution of
ASWA could be discussed within the framework of a neu-
rodevelopmental model of schizophrenia [52] as one of
the "downstream or tangential manifestations of the core
neurobiological phenotype, viz. the genetically influ-
enced molecular disruption of neural circuits" (p. 41).
One intriguing possibility is that morphological changes
like loss of gray matter provide one basis or substrate for
functional changes in neuronal network architecture and
communication. As to what extent this could be related to
Mean fronto-central ASWA (Z-scores averaged across the  left- and right-frontal and the left- and right central regions,  ordinate) are plotted separately for the three groups (filled  circles: controls, squares: schizophrenia patients, triangles:  patients with affective or neurotic/reactive diagnoses) and for  age categories (abscissa: <20 yrs: n = 4 controls, 5 schizo- phrenics, 0 affective/neurotic patients 17–19 years of age;  20–29: n = 74 controls, 34 schizophrenics, 0 affective/neu- rotic patients between 20 and 29 years of age; 30–39: n = 26  controls, 28 schizophrenics, 10 affective/neurotic patients  between 30 and 39 years; 40–49: n = 4 controls, 8 schizo- phrenics, 15 affective/neurotic patients between 40 and 49  years; 50–59: n = 3 controls, 1 schizophrenic, 13 affective/ neurotic patients between 50 and 59 years; 60+: n = 5 con- trols, 0 schizophrenic, and 3 affective/neurotic patients 60  years and older) Figure 2
Mean fronto-central ASWA (Z-scores averaged across the 
left- and right-frontal and the left- and right central regions, 
ordinate) are plotted separately for the three groups (filled 
circles: controls, squares: schizophrenia patients, triangles: 
patients with affective or neurotic/reactive diagnoses) and for 
age categories (abscissa: <20 yrs: n = 4 controls, 5 schizo-
phrenics, 0 affective/neurotic patients 17–19 years of age; 
20–29: n = 74 controls, 34 schizophrenics, 0 affective/neu-
rotic patients between 20 and 29 years of age; 30–39: n = 26 
controls, 28 schizophrenics, 10 affective/neurotic patients 
between 30 and 39 years; 40–49: n = 4 controls, 8 schizo-
phrenics, 15 affective/neurotic patients between 40 and 49 
years; 50–59: n = 3 controls, 1 schizophrenic, 13 affective/
neurotic patients between 50 and 59 years; 60+: n = 5 con-
trols, 0 schizophrenic, and 3 affective/neurotic patients 60 
years and older). Symbols indicate mean values, bars standard 
deviation.BMC Psychiatry 2007, 7:44 http://www.biomedcentral.com/1471-244X/7/44
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weakened connectivity, which has been hypothesized for
schizophrenic disorders [53], remains to be substantiated
by combining ASWA mapping with measures of connec-
tivity in future studies.
It should be noted that the present results of extended
ASWA in schizophrenic patients replicate our previous
findings, although they did not substantiate a left-hemi-
spheric and temporal focus of ASWA as described in
[19,35]. These differences may be attributed to three dif-
ferences between the present study and our previous
work. First, in the current study we followed a more pre-
cise anatomical atlas [42] for the definition of regions of
topographical analysis, whereas previous work measured
activity simply in eight cubes of equal size. Thus, it may
well be that the presently defined frontal and central
regions included areas such as the cingulum or orbitof-
rontal cortex that had been attributed to the 'temporal'
cubes in the former study. Second, the present analysis
comprised of a more detailed determination of slow wave
generators within voxels, which might have resulted on a
more sensitive detection of ASWA. Third, the present
study included a larger sample size, which could have
influenced the results: The present group of 116 healthy
subjects might represent 'normality' better than a control
group of some 20 subjects. Likewise, the present sample of
76 schizophrenic patients might represent a larger and,
hence, more realistic spectrum of clinical characteristics
than the previous more strictly selected sample of some 20
male patients, all meeting a F20 diagnoses and other
selection criteria.
In schizophrenic patients anterior ASWA varied with
affective symptoms. This was best seen in terms of a lack
of affective modulation rather than with depressive affect.
Although this could be related to affective modulation in
orbitofrontal regions, it does seem intriguing that dys-
functional neuronal network communication did not
vary with more cognitive dysfunction – as was found in
earlier studies [19] and also in relation to gray matter loss
[51,54]. However, a complex and dynamic transition
from causes of schizophrenia to the level of symptoms
might not become manifest in a simple relationship
between ASWA (measured under laboratory conditions)
and those clinical measures that are used to characterize
the schizophrenic state on the ward (like BPRS and
PANSS).
In order to rule out alternative explanations for our
results, we examined demographic and clinical variables
in relation to ASWA. The gender effect on ASWA is a
potential confound. However, results did not change,
when gender is included as a between-subjects factor. In
particular, there was no interaction with the factor for
diagnostic groups. In addition, we probed the gender
effect separately in the diagnostic groups: the 14 female
schizophrenics displayed pronounced frontal and tempo-
ral ASWA similar to that of the 62 male patients. In fact,
the frontal ASWA excess in female schizophrenia patients
contrasts the "female" pattern of lower-than-average fron-
tal ASWA, which was displayed by controls. In the affec-
tive/neurotic sample, the 13 male patients did not differ
from the 28 female subjects with respect to lower-than-
normal frontal and equal-to-normal central ASWA. Effects
of medication on the human EEG/MEG always present a
potential confound in the interpretation of data of any
study, but are difficult to evaluate, as unmedicated
patients may differ in most clinical studies in their symp-
tom profile from medicated ones. Moreover, findings for
the influence of medication may be two-fold: The drug
may act directly on brain activity and/or indirectly via
clinical improvement. Therefore it seems not surprising
that results are inconsistent: as a slowing of EEG frequen-
cies has been reported as a consequence of neuroleptic
medication, but also 'normalizing' effects [27,55-57]. In
the present study, there was only a suggestion that typical
neuroleptics like haloperidol reduced ASWA more than
atypical neuroleptics. Given that assignment to medica-
tion was not random, but followed clinical guidelines,
more specific conclusions about the effect of medication
on ASWA must remain speculative. In addition, clinical
variables rarely exist independently. For example, symp-
tom scores might vary with duration of illness, medica-
tion or cannabis abuse, and in their combination or
interaction affect neuronal network communication.
The present study also found lower-than-normal slow
wave activity in patients hospitalized for affective/neu-
rotic disorders, mainly depression. Decreased EEG slow
wave activity in depression has been reported before
[58,59]. Our results disclosed a pattern of less slow wave
activity, mainly in the anterior central regions and mainly
in patients suffering from recurrent depressive episodes
which might signal a more severe form of the disorder.
From quantitative EEG (qEEG) analysis, Pozzi et al. [59]
distinguished a posterior increase in delta power in
depressed patients with dementia compared to a global
decrease in delta power in depressives without dementia.
Posterior dominance of ASWA has been demonstrated in
patients with Alzheimer dementia [29], but a relationship
between depression and dementia was not explored in the
present sample. Indirect support for the pathological sig-
nificance of reduced slow wave activity can be inferred
from its (left-frontal) increase after successful electrocon-
vulsive therapy [60]. Moreover, PET studies disclosed
hypometabolism in the inferior frontal lobe [61,62] and
prefrontal cortex [63] in depression. However, compara-
bility to other findings does not allow more specific
hypotheses about the functional meaning of the lower
frontal ASWA in affective/neurotic disorders. As to whatBMC Psychiatry 2007, 7:44 http://www.biomedcentral.com/1471-244X/7/44
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extent the lower-than-normal frontal ASWA characterizes
affective psychopathology or the anterior-posterior gradi-
ent, that is, more pronounced ASWA in posterior regions,
must to be clarified by future studies.
A final question is to what extent ASWA markers may
assist in diagnosis and treatment. Historically, Lewine &
Orrison [17] recommended the method and the measure
for the mapping of dysfunctional brain tissue. Derived
from neurological evidence, 'dysfunction' was described
as a state of less information transfer within and across
networks. These slow oscillations were thought to indicate
less exchange of excitation as they have been related to
hypometabolism and reduced blood flow [18]. De Jongh
[8,9] suggested that ASWA results from damage done by
structural lesion on surrounding white/gray matter rather
than resulting from the lesion itself. The surrounding tis-
sue may be considered in a state of disconnection or de-
afferentation. The present paper along with previous ones
demonstrates that ASWA may be seen in psychopathol-
ogy. One possibility would therefore be to test this meas-
ure as an indicator for the progress in the damage of brain
circuits. For example, patients with high but not low val-
ues might be tested if they respond positively to attempts
to ameliorate dementia and to stimulate neurogenesis.
Conclusion
The different patterns of ASWA in groups of patients with
different psychiatric diagnoses suggest that mapping
abnormal slow wave activity might allow for differentiat-
ing individuals with psychiatric diagnoses from normal
controls and potentially also to differentiate different
diagnostic groups. As a relatively new measure, ASWA at
present must be considered a descriptive measure for
which quite different explanations have been proposed. A
crucial next step in this process of evaluation would be
further clarification of the functional meaning of ASWA.
The neurodevelopmental perspective of psychiatric disor-
ders like schizophrenia [52] suggests that ASWA is a man-
ifestation of disrupted formation of neural circuits,
facilitating lasting histological anomalies like gray matter
loss, 'disconnection' or the vulnerability for its develop-
ment. Finally, if 'dysfunctional' implies a transient nature
of the phenomenon and not a neurodevelopmentally
determined lasting nature, then it should be possible to
see changes in ASWA following treatment for the disorder.
Given that systematic changes in the intensity of ASWA
could be achieved by training in aphasic patients [21] we
have started to examine ASWA in patients suffering from
depression and posttraumatic stress disorder before and
after treatment. Taken together, this might open an
intriguing possibility to use ASWA mapping as an addi-
tional tool in the diagnostic and prognostic process and in
treatment evaluation.
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